Inhibition of fatty acid amide hydrolase produces PPAR-α-mediated analgesia in a rat model of inflammatory pain

British Journal of Pharmacology

Volumn 155, Issue 8, 2008, Pages 1297-1306

  Sagar, D R ^a   Kendall, D A ^a   Chapman, V ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Endocannabinoid; Inflammation; Pain; PPAR; Spinal electrophysiology

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; [[(2) 2 [[(1) 1 METHYL 3 OXO 3 [4 (TRIFLUOROMETHYL)PHENYL] 1 PROPENYL]AMINO] 3 [4 [2 (5 METHYL 2 PHENYL 4 OXA ZOLYL)ETHOXY]PHENYL]PROPYL]CARBAMIC ACID ETHYL ESTER]; CARRAGEENAN; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; FATTY ACID AMIDASE; GW 6471; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PIRINIXIC ACID; UNCLASSIFIED DRUG;

ANALGESIA; ANTINOCICEPTION; ARTICLE; DRUG EFFECT; ENZYME INHIBITION; EVOKED RESPONSE; MECHANICAL STIMULATION; PAIN; PRIORITY JOURNAL; RECEPTIVE FIELD; SPINAL CORD DORSAL HORN; SPINAL CORD NERVE CELL; TREATMENT RESPONSE;

AMIDOHYDROLASES; ANALGESIA; ANIMALS; BENZAMIDES; CARBAMATES; CARRAGEENAN; DISEASE MODELS, ANIMAL; INFLAMMATION; OXAZOLES; PAIN; PIPERIDINES; PPAR GAMMA; PYRAZOLES; RATS; RECEPTOR, CANNABINOID, CB1; TYROSINE;

EID: 57349146897     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.335     Document Type: Article

References (47)

1. Calignano A, La Rana G, Giuffrida A, Piomelli D (1998). Control of pain initiation by endogenous cannabinoids. Nature 394: 277-281.
2. Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ et al. (2006). Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 148: 102-113.
3. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL (1994). Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53: 55-63.
4. Colville-Nash P, Willis D, Papworth J, Freemantle C, Lam C, Andrews G et al. (2005). The peroxisome proliferator-activated receptor alpha activator, Wy14643, is anti-inflammatory in vivo. Inflammopharmacology 12: 493-504.
5. Cravatt BF, Saghatelian A, Hawkins EG, Clement AB, Bracey MH, Lichtman AH (2004). Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci USA 101: 10821-10826.
6. Cunard R, DiCampli D, Archer DC, Stevenson JL, Ricote M, Glass CK et al. (2002). WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo. J Immunol 169: 6806-6812.
7. Cunha JM, Cunha FQ, Poole S, Ferreira SH (2000). Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. Br J Pharmacol 130: 1418-1424.
8. D'Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E et al. (2007). Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. J Pharmacol Exp Ther 322: 1137-1143.
9. Delayre-Orthez C, Becker J, Guenon I, Lagente V, Auwerx J, Frossard N et al. (2005). PPARalpha downregulates airway inflammation induced by lipopolysaccharide in the mouse. Respir Res 6: 91.
10. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949.
11. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W (1996). The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384: 39-43.
12. Elmes SJ, Jhaveri MD, Smart D, Kendall DA, Chapman V (2004). Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci 20: 2311-2320.
13. Francois M, Richette P, Tsagris L, Fitting C, Lemay C, Benallaoua M et al. (2006). Activation of the peroxisome proliferator-activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes. Arthritis Rheum 54: 1233-1245.
14. Guay J, Bateman K, Gordon R, Mancini J, Riendeau D (2004). Carrageenan-induced paw edema in rat elicits a predominant prostaglandin e2 (pge2) response in the central nervous system associated with the induction of microsomal PGE2 synthase-1. J Biol Chem 279: 24866-24872.
15. Guindon J, Desroches J, Beaulieu P (2007). The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br J Pharmacol 150: 693-701.
16. Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988). A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32: 77-88.
17. Holt S, Comelli F, Costa B, Fowler CJ (2005). Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br J Pharmacol 146: 467-476.
18. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW (2006). Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147: 281-288.
19. Jhaveri MD, Richardson D, Chapman V (2007). Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol 152: 624-632.
20. Jhaveri MD, Richardson D, Kendall DA, Barrett DA, Chapman V (2006). Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 26: 13318-13327.
21. Jhaveri MD, Richardson D, Robinson I, Garle MJ, Patel A, Sun Y et al. (2008). Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology 55: 85-93.
22. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76-81.
23. Kelly S, Jhaveri MD, Sagar DR, Kendall DA, Chapman V (2003). Activation of peripheral cannabinoid CB1 receptors inhibits mechanically evoked responses of spinal neurons in noninflamed rats and rats with hindpaw inflammation. Eur J Neurosci 18: 2239-2243.
24. Lichtman AH, Shelton CC, Advani T, Cravatt BF (2004). Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109: 319-327.
25. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A et al. (2005). The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67: 15-19.
26. Loram LC, Fuller A, Fick LG, Cartmell T, Poole S, Mitchell D (2007). Cytokine profiles during carrageenan-induced inflammatory hyperalgesia in rat muscle and hind paw. J Pain 8: 127-136.
27. LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G et al. (2006). Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther 319: 1051-1061.
28. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90.
29. Merrill EG, Ainsworth A (1972). Glass-coated platinum-plated tungsten microelectrodes. Med Biol Eng 10: 662-672.
30. Moraes LA, Piqueras L, Bishop-Bailey D (2006). Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 110: 371-385.
31. Morris CJ (2003). Carrageenan-induced paw edema in the rat and mouse. In: Winyard PG, Willoughby D (eds). Inflammation Protocols, vol. 225 Humana Press: Totowa, New Jersey, pp 115-121.
32. Murakami K, Bujo H, Unoki H, Saito Y (2007). Effect of PPARalpha activation of macrophages on the secretion of inflammatory cytokines in cultured adipocytes. Eur J Pharmacol 561: 206-213.
33. Nackley AG, Zvonok AM, Makriyannis A, Hohmann AG (2004). Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol 92: 3562-3574.
34. Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A et al. (2003). Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 99: 955-960.
35. Richardson JD, Kilo S, Hargreaves KM (1998). Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75: 111-119.
36. Rockwell CE, Kaminski NE (2004). A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes. J Pharmacol Exp Ther 311: 683-690.
37. Rockwell CE, Snider NT, Thompson JT, Vanden Heuvel JP, Kaminski NE (2006). Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol Pharmacol 70: 101-111.
38. Russo R, Loverme J, La Rana G, Compton TR, Parrott J, Duranti A et al. (2007). The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 30-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 322: 236-242.
39. Sokal DM, Elmes SJ, Kendall DA, Chapman V (2003). Intraplantar injection of anandamide inhibits mechanically-evoked responses of spinal neurones via activation of CB2 receptors in anaesthetised rats. Neuropharmacology 45: 404-411.
40. Stienstra R, Mandard S, Tan NS, Wahli W, Trautwein C, Richardson TA et al. (2007). The interleukin-1 receptor antagonist is a direct target gene of PPARalpha in liver. J Hepatol 46: 869-877.
41. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K et al. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215: 89-97.
42. Sun Y, Alexander SPH, Garle MJ, Gibson CL, Hewitt K, Murphy SP et al. (2007). Cannabinoid activation of PPAR[alpha]; a novel neuroprotective mechanism. Br J Pharmacol 152: 734-743.
43. Tham CS, Whitaker J, Luo L, Webb M (2007). Inhibition of microglial fatty acid amide hydrolase modulates LPS stimulated release of inflammatory mediators. FEBS Lett 581: 2899-2904.
44. Torsney C, Fitzgerald M (2003). Spinal dorsal horn cell receptive field size is increased in adult rats following neonatal hindpaw skin injury. J Physiol 550: 255-261.
45. Tsuboi K, Takezaki N, Ueda N (2007). The N-acylethanolaminehydrolyzing acid amidase (NAAA). Chem Biodivers 4: 1914-1925.
46. Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC (1999). Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 96: 12198-12203.
47. Wise LE, Cannavacciulo R, Cravatt BF, Martin BF, Lichtman AH (2008). Evaluation of fatty acid amides in the carrageenan-induced paw edema model. Neuropharmacology 54: 181-188.